![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Qiagen Gets CE Mark for COVID-19, Influenza A and B, RSV Test
Qiagen Gets CE Mark for COVID-19, Influenza A and B, RSV Test
Qiagen has received the CE mark for its QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 test, which runs on the company’s QIAstat-Dx system.
The test is intended to quickly identify whether patients have common seasonal respiratory infections or COVID-19, according to the Hilden, Germany, and Germantown, Md.-based company. It uses a modular cartridge-based system to deliver fast results that require no additional sample preparation.
Qiagen says it recently expanded the QIAstat-Dx testing menu with a respiratory four-plex panel that differentiates between flu, RSV and COVID-19. It will be especially useful, the company says, in influenza-like illness or flu seasons.
Related Events
Upcoming Events
-
11Jul
-
18Jul
-
21Oct